Literature DB >> 1864298

Use of quinolones in the immunocompromised host.

A G Maiche1.   

Abstract

Immune deficiency generally leads to infections. Cancer chemotherapy, medical interventions and various investigational procedures are important factors in the development of infection. In recent decades, there has been a major change in most cancer centers in the etiology of bacterial infections occurring in the immunocompromised host, most infections now being caused by gram-positive organisms. This might be partly due to prophylactic use of agents effective against gram-negative bacteria. The quinolones are now widely used in the treatment of serious infections of the immunocompromised patient. Prophylaxis with quinolones is also practised in cancer centers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1864298     DOI: 10.1007/bf01967012

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  23 in total

1.  Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract.

Authors:  D T Sleijfer; N H Mulder; H G de Vries-Hospers; V Fidler; H O Nieweg; D van der Waaij; H K van Saene
Journal:  Eur J Cancer       Date:  1980-06       Impact factor: 9.162

Review 2.  Use of quinolones for the treatment of patients with bacteremia.

Authors:  P M Shah
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

3.  Norfloxacin for prevention of bacterial infections in granulocytopenic patients.

Authors:  D J Winston; W G Ho; R E Champlin; J Karp; J Bartlett; R S Finley; J H Joshi; G Talbot; L Levitt; S Deresinski
Journal:  Am J Med       Date:  1987-06-26       Impact factor: 4.965

4.  Antimicrobial prophylaxis in immunocompromised patients.

Authors:  J H Hartlapp
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  Infection prevention during profound granulocytopenia. New approaches to alimentary canal microbial suppression.

Authors:  S C Schimpff
Journal:  Ann Intern Med       Date:  1980-08       Impact factor: 25.391

6.  Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis.

Authors:  E J Bow; E Rayner; T J Louie
Journal:  Am J Med       Date:  1988-05       Impact factor: 4.965

7.  Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora.

Authors:  M Rozenberg-Arska; A W Dekker; J Verhoef
Journal:  J Infect Dis       Date:  1985-07       Impact factor: 5.226

8.  Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia.

Authors:  Thierry Calandra; J Klastersky; H Gaya; M P Glauser; F Meunier; S H Zinner
Journal:  N Engl J Med       Date:  1987-12-31       Impact factor: 91.245

9.  Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia.

Authors:  J C Wade; S C Schimpff; K A Newman; P H Wiernik
Journal:  Ann Intern Med       Date:  1982-10       Impact factor: 25.391

10.  Systemic infection and colonization with and without prophylactic norfloxacin use over time in the granulocytopenic, acute leukemia patient.

Authors:  J E Karp; J D Dick; W G Merz
Journal:  Eur J Cancer Clin Oncol       Date:  1988
View more
  2 in total

1.  In vitro antibiotic susceptibility testing of clinical isolates of Mycoplasma penetrans from patients with AIDS.

Authors:  M M Hayes; H H Foo; J Timenetsky; S C Lo
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

Review 2.  Quinolone antibacterials. An update of their pharmacology and therapeutic use.

Authors:  N von Rosenstiel; D Adam
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.